Home

OrbiMed Capital GP IV LLC

CIK 1502240 · last filed 2024-07-02

OrbiMed Capital GP IV LLC is a corporate insider who has filed 30 SEC Form 4 insider transactions across 9 companies since 2010. The most recent filing shows the insider sold $4.0M of TELA on Jul 2, 2024. Across all open-market trades the lifetime net is −$678.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $21.1M across reported positions. The firm reports its address in New York, NY. 78 SEC filings were submitted jointly with ORBIMED ADVISORS LLC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$21.12M

Companies

9

Total Filings

30

Lifetime Open-Market Net

-$678.12M

Filer Profile

Reported Address
601 LEXINGTON AVENUE, 54TH FLOOR
NEW YORK, NY 10022
Phone
(212) 739-6400
State of Incorporation
DE
Related Filers
ORBIMED ADVISORS LLC — 78 joint filings, latest 2024-07-02
SAMUEL D ISALY — 52 joint filings, latest 2017-11-20
ORBIMED CAPITAL LLC — 6 joint filings, latest 2020-03-04
OrbiMed Capital GP V LLC — 3 joint filings, latest 2018-06-22
Orbimed ROF II LLC — 3 joint filings, latest 2021-07-21
OrbiMed Capital GP VI LLC — same reported address
OrbiMed Capital GP VII LLC — same reported address
OrbiMed Genesis GP LLC — same reported address
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
TELA 10%+ Owner 5,485,084 $0.97 $5.32M $5.96M 2 2024-07-02
ALEC 10%+ Owner 1,921,804 $2.14 $4.11M -$244.48M 7 2020-04-16
Principia Biopharma Inc. (PRNB) Delisted 10%+ Owner 1,605,713 — — -$52.00M 2 2019-05-22
BOLD 10%+ Owner 4,129,638 $2.83 $11.69M -$56.95M 1 2017-09-29
Relypsa Inc (RLYP) Delisted 10%+ Owner 7,664,171 — — -$233.05M 6 2015-12-23
OTONOMY, INC. (OTIC) Delisted Director 2,245,300 $0.08 $172.9K -$11.88M 1 2015-11-19
INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted Director 1,120,609 $19.00 $21.29M -$84.48M 5 2015-07-21
Mirati Therapeutics, Inc. (MRTX) Delisted 10%+ Owner 1,267,000 $58.70 $74.37M $6.00M 1 2015-02-05
Anthera Pharmaceuticals Inc (ANTH) Delisted Director 116,594 — — -$7.23M 5 2013-02-01

Recent Filings

30 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2024-07-02 TELA Sell (S) −856,600 -$4.04M EDGAR
2020-04-16 ALEC Sell (S) −170,828 -$4.02M EDGAR
2020-04-09 ALEC Sell (S) −759,770 -$18.04M EDGAR
2020-04-02 ALEC Sell (S) −500,000 -$12.25M EDGAR
2020-03-25 ALEC Sell (S) −277,306 -$6.85M EDGAR
2020-03-04 ALEC Sell (S) −5,622,609 -$146.19M EDGAR
2020-01-13 ALEC Sell (S) −1,139,991 -$22.23M EDGAR
2019-11-13 TELA Mixed +3,687,060 $10.00M EDGAR
2019-08-09 ALEC Sell (S) −1,950,000 -$34.91M EDGAR
2019-05-22 Principia Biopharma Inc. (PRNB) Delisted Sell (S) −2,000,000 -$60.50M EDGAR
Showing 1–10 of 30
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.